Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics


Dr. Reddy's Laboratories Ltd (RDY)

Today's Latest Price: $71.06 USD

0.95 (-1.32%)

Updated Jan 15 7:00pm

Add RDY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RDY Stock Summary

  • The price/operating cash flow metric for Dr Reddys Laboratories Ltd is higher than just 2.3% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of -41.16%, Dr Reddys Laboratories Ltd's debt growth rate surpasses only 7.68% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for RDY comes in at 196.81% -- higher than that of 98.39% of stocks in our set.
  • Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are AGCO, ITT, BRKR, FINV, and VAR.
  • RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.

RDY Stock Price Chart Interactive Chart >

Price chart for RDY

RDY Price/Volume Stats

Current price $71.06 52-week high $73.50
Prev. close $72.01 52-week low $33.33
Day low $70.60 Volume 164,000
Day high $71.44 Avg. volume 172,500
50-day MA $67.80 Dividend yield 0.38%
200-day MA $60.03 Market Cap 11.78B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio


Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$71.06$2080.28 2789%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dr Reddys Laboratories Ltd. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 93th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 2803.17% on a DCF basis. The most interesting components of our discounted cash flow analysis for Dr Reddys Laboratories Ltd ended up being:

  • The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately only 11.39% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Dr Reddys Laboratories Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than merely 0% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%2732%
1%2761%
2%2789%
3%2817%
4%2846%
5%2874%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RDY, try BEAT, OMI, CORT, FVE, and ALPN.


RDY Latest News Stream


Event/Time News Detail
Loading, please wait...

RDY Latest Social Stream


Loading social stream, please wait...

View Full RDY Social Stream

Latest RDY News From Around the Web

Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.

Dr. reddy’s gets green light for phase 3 clinical trial for sputnik V COVID-19 vaccine in India

Dr. Reddy’s Laboratories ([[RDY]] -1.7%) says that the Drugs Control General of India ((DCGI)) has given it the go-ahead to conduct phase 3 clinical trial for the Sputnik V COVID-19 vaccine in India, a day ahead of the scheduled mass vaccination drive in the country.The phase 3 study of Sputnik V will be conducted...

Seeking Alpha | January 15, 2021

Dr. Reddy’s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India

Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.

Yahoo | January 15, 2021

Dr. Reddy's to Release Q3 FY 21 Results on January 29th, 2021

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31, 2020 on Friday, January 29th, 2021 after the Board Meeting.

Yahoo | January 8, 2021

Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada’s Interim Order

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response Aid FZCO (GRA) today announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. REEQONUS™ is also known as Avigan® (favipiravir) Tablets, developed by FUJIFILM Toyama Chemical Co., Ltd.

Yahoo | December 22, 2020

Sensex slips into red after hitting 47K for the first time​​

In the 50-share pack Nifty, HCL Tech was the biggest gainer, up 2.39 per cent. Infosys, TCS, Dr Reddys Laboratories, Nestle India, Wipro, Bajaj Auto and UltraTech Cement were among other gainers.

Economic Times India | December 17, 2020

Read More 'RDY' Stories Here

RDY Price Returns

1-mo 0.74%
3-mo 4.59%
6-mo 30.22%
1-year 68.29%
3-year 89.41%
5-year 72.12%
YTD -0.32%
2020 76.61%
2019 8.38%
2018 1.18%
2017 -16.47%
2016 -1.67%

RDY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8128 seconds.